Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $10.1 million.

  • Cytosorbents' Total Current Liabilities rose 2206.06% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 2206.06%. This contributed to the annual value of $9.8 million for FY2024, which is 2999.94% down from last year.
  • Cytosorbents' Total Current Liabilities amounted to $10.1 million in Q3 2025, which was up 2206.06% from $9.8 million recorded in Q2 2025.
  • Cytosorbents' Total Current Liabilities' 5-year high stood at $14.7 million during Q1 2022, with a 5-year trough of $8.3 million in Q3 2024.
  • For the 5-year period, Cytosorbents' Total Current Liabilities averaged around $10.8 million, with its median value being $10.1 million (2025).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 3621.7% in 2021, then surged by 5033.66% in 2022.
  • Cytosorbents' Total Current Liabilities (Quarter) stood at $13.7 million in 2021, then decreased by 29.04% to $9.7 million in 2022, then surged by 44.48% to $14.0 million in 2023, then decreased by 30.0% to $9.8 million in 2024, then grew by 2.92% to $10.1 million in 2025.
  • Its Total Current Liabilities stands at $10.1 million for Q3 2025, versus $9.8 million for Q2 2025 and $9.7 million for Q1 2025.